Skip to content

QUICK_START.md

Latest commit

 

History

History
112 lines (88 loc) · 3.89 KB

QUICK_START.md

File metadata and controls

112 lines (88 loc) · 3.89 KB

Drug Target Validation - Quick Start Guide

Overview

This skill validates drug target hypotheses using computational evidence from 60+ ToolUniverse tools. It produces a Target Validation Score (0-100) with a GO/NO-GO recommendation.

Basic Usage

Use Case 1: Full Target Validation (Disease-Specific)

Is KRAS a druggable target for pancreatic cancer?

What happens: Full 10-phase analysis with disease-specific evidence, produces validation score and GO/NO-GO recommendation.

Use Case 2: General Target Druggability Assessment

Assess the druggability of BTK as a therapeutic target

What happens: Focuses on druggability, chemical matter, structural tractability, and clinical precedent without disease-specific filtering.

Use Case 3: Target Safety Assessment

What are the safety risks of inhibiting IDH1?

What happens: Emphasizes safety phase - expression in critical tissues, knockout phenotypes, known adverse events, paralogs.

Use Case 4: Chemical Starting Points

What compounds are available for PCSK9 validation?

What happens: Deep dive into chemical matter - ChEMBL activities, BindingDB ligands, PubChem bioassays, chemical probes.

Use Case 5: Target Comparison

Compare PD-1 vs PD-L1 as immunotherapy targets

What happens: Runs validation pipeline for both targets, produces side-by-side comparison of scores.

Use Case 6: Novel Target Evaluation

Is TEAD4 a viable target for solid tumors? Consider small molecule approach.

What happens: Full validation with modality-specific analysis, extra focus on structural tractability for small molecules.

Output

Every analysis produces a markdown report file with:

  1. Executive Summary with GO/NO-GO recommendation
  2. Validation Scorecard (0-100 composite score)
  3. 10 Detailed Sections covering all evidence dimensions
  4. Validation Roadmap with recommended experiments
  5. Risk Assessment with mitigation strategies
  6. Completeness Checklist showing analysis coverage

Priority Tiers

Score Tier Meaning
80-100 Tier 1 Highly validated - proceed with confidence
60-79 Tier 2 Good target - needs focused validation
40-59 Tier 3 Moderate risk - significant validation needed
0-39 Tier 4 High risk - consider alternatives

Evidence Grades

  • [T1]: Direct mechanistic evidence (crystal structure, patient mutations, FDA-approved drug)
  • [T2]: Functional studies (CRISPR KO, mouse model, biochemical assay)
  • [T3]: Association (GWAS hit, DepMap essentiality, expression correlation)
  • [T4]: Annotation (database entry, computational prediction, review article)

Example Report Structure

EGFR_NSCLC_validation_report.md

Executive Summary
  Score: 90/100 | Tier 1 | GO
  Strong genetic + clinical validation for NSCLC

Validation Scorecard
  Disease Association:   28/30
  Druggability:          24/25
  Safety Profile:        14/20
  Clinical Precedent:    15/15
  Validation Evidence:    9/10

[10 detailed sections with tool outputs and evidence]

Validation Roadmap
  - Recommended experiments
  - Tool compounds
  - Biomarker strategy
  - Risk mitigations

Key Databases Queried

Database Information Tools
OpenTargets Disease associations, tractability, safety 15+ tools
ChEMBL Bioactivity, compounds, mechanisms 8+ tools
PDB/AlphaFold 3D structures, binding pockets 12+ tools
STRING/IntAct Protein interactions 6+ tools
GTEx/HPA Tissue expression 10+ tools
GWAS Catalog Genetic associations 5+ tools
FDA/DrugBank Approved drugs, safety 10+ tools
ClinicalTrials.gov Clinical development 2+ tools
PubMed/EuropePMC Literature evidence 6+ tools
gnomAD Genetic constraint 2+ tools
DepMap Cancer essentiality 3+ tools
Reactome Biological pathways 5+ tools